Gaëlle Thomas

Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy

Wilhem Leconet, Christel Larbouret, Thierry Chardès et al. · Oncogene · 2013 · 106 citations · Full text

Medicine, Cancer Biology, Oncology +14

Dolutegravir Monotherapy Versus Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed People Living With Chronic Human Immunodeficiency Virus Infection: The Randomized Noninferiority MONotherapy of TiviCAY Trial

Laurent Hocqueloux, François Raffi, Thiérry Prazuck et al. · Clinical Infectious Diseases · 2018 · 58 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer

Charline Ogier, Pierre‐Emmanuel Colombo, Corinne Bousquet et al. · Cancer Letters · 2018 · 57 citations

Medicine, Cancer Biology, Oncology +10

HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models

Gaëlle Thomas, Thierry Chardès, Nadège Gaborit et al. · Oncotarget · 2014 · 44 citations · Full text

Medicine, Oncology, Pharmacology +14

Anti-HER3 Domain 1 and 3 Antibodies Reduce Tumor Growth by Hindering HER2/HER3 Dimerization and AKT-Induced MDM2, XIAP, and FoxO1 Phosphorylation

Yassamine Lazrek, Olivier Dubreuil, Véronique Garambois et al. · Neoplasia · 2013 · 38 citations · Full text

Medicine, Oncology, Pharmacology +16